CD318 as a marker for, and CD318 inhibition as a treatment for, autoimmune disease
Provided herein are compositions, systems, kits, and methods for detecting autoimmune disease (e.g., multiple sclerosis and juvenile idiopathic arthritis), and risk of autoimmune disease, in a subject based on the levels of CD318.
1. A method of performing an activity based on a level of CD318 protein or mRNA in a sample from a human subject comprising:
a) determining protein and/or mRNA expression level of CD318 in a sample from a human subject, with, or suspected of having, an autoimmune disease; and
b) identifying increased protein and/or mRNA expression levels of CD318 in said sample, and treating said subject with a therapeutic agent used to treat an autoimmune disease;
wherein said autoimmune disease is rheumatoid arthritis, juvenile inflammatory arthritis, or multiple sclerosis, and
wherein said therapeutic agent comprises an anti-CD318 antibody or antigen binding fragment thereof, or an anti-CD318 siRNA.
2. The method of claim 1 , wherein said sample is selected from the group consisting of: a plasma sample, a serum sample, synovial fluid sample, and synovial tissue sample.
3. The method of claim 1 , wherein said determining comprises contacting said sample with an anti-CD318 antibody.
4. A method of treatment comprising:
a) identifying a human subject as having increased expression levels of CD318 protein and/or mRNA, wherein said subject has, or is suspected of having, rheumatoid arthritis, juvenile inflammatory arthritis, or multiple sclerosis, and
b) treating said subject with a therapeutic agent, wherein said therapeutic agent is an anti-CD318 antibody or antigen binding fragment thereof, or an anti-CD318 siRNA.
5. The method of claim 4 , wherein said identifying comprises receiving a report that said subject has increased expression levels of CD318 protein and/or mRNA.